Utility of multispectral imaging in automated quantitative scoring of immunohistochemistryShow others and affiliations
2012 (English)In: Journal of Clinical Pathology, ISSN 0021-9746, E-ISSN 1472-4146, Vol. 65, no 6, p. 496-502Article in journal (Refereed) Published
Abstract [en]
Background: Automated scanning devices and image analysis software provide a means to overcome the limitations of manual semiquantitative scoring of immunohistochemistry. Common drawbacks to automated imaging systems include an inability to classify tissue type and an inability to segregate cytoplasmic and nuclear staining.
Methods: Immunohistochemistry for the membranous marker a-catenin, the cytoplasmic marker stathmin and the nuclear marker Ki-67 was performed on tissue microarrays (TMA) of archival formalin-fixed paraffin-embedded tissue comprising 471 (alpha-catenin and stathmin) and 511 (Ki-67) cases of prostate adenocarcinoma. These TMA were quantitatively analysed using two commercially available automated image analysers, the Ariol SL-50 system and the Nuance system from CRi. Both systems use brightfield microscopy for automated, unbiased and standardised quantification of immunohistochemistry, while the Nuance system has spectral deconvolution capabilities. Results Overall concordance between scores from both systems was excellent (r=0.90; 0.83-0.95). The software associated with the multispectral imager allowed accurate automated classification of tissue type into epithelial glandular structures and stroma, and a single-step segmentation of staining into cytoplasmic or nuclear compartments allowing independent evaluation of these areas. The Nuance system, however, was not able to distinguish reliably between tumour and non-tumour tissue. In addition, variance in the labour and time required for analysis between the two systems was also noted.
Conclusion: Despite limitations, this study suggests some beneficial role for the use of a multispectral imaging system in automated analysis of immunohistochemistry.
Place, publisher, year, edition, pages
London, United Kingdom: BMJ Publishing Group Ltd, 2012. Vol. 65, no 6, p. 496-502
National Category
Medical and Health Sciences Cancer and Oncology
Research subject
Medicine
Identifiers
URN: urn:nbn:se:oru:diva-23697DOI: 10.1136/jclinpath-2012-200734ISI: 000304609900003PubMedID: 22447914Scopus ID: 2-s2.0-84862827080OAI: oai:DiVA.org:oru-23697DiVA, id: diva2:536809
Note
Funding Agencies:
Prostate Cancer Foundation
National Cancer Institute
Linda and Arthur Gelb Center for Translational Research
Dana Farber Cancer Institute-Novartis
2012-06-252012-06-252018-05-09Bibliographically approved